# | Title | Journal | Year | Citations |
---|
1 | 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer | Journal of Nuclear Medicine | 2019 | 874 |
2 | Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2020 | 710 |
3 | Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial | Lancet Respiratory Medicine,the | 2019 | 704 |
4 | First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers | Journal of Clinical Oncology | 2019 | 457 |
5 | Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2022 | 445 |
6 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2019 | 418 |
7 | Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial | Lancet Respiratory Medicine,the | 2016 | 349 |
8 | Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial | Journal of Thoracic Oncology | 2021 | 323 |
9 | Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 | Annals of Oncology | 2021 | 213 |
10 | IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC | Journal of Thoracic Oncology | 2021 | 212 |
11 | Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis | American Journal of Respiratory and Critical Care Medicine | 2017 | 169 |
12 | Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination | European Respiratory Journal | 2013 | 163 |
13 | Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study | Journal of Clinical Oncology | 2021 | 146 |
14 | Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches | Annals of Oncology | 2021 | 134 |
15 | Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2020 | 119 |
16 | IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain | Journal of Thoracic Oncology | 2022 | 114 |
17 | Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer | JAMA Oncology | 2021 | 113 |
18 | Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD | Respiratory Medicine | 2015 | 108 |
19 | Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer | JAMA Oncology | 2021 | 105 |
20 | Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease | Chest | 2018 | 102 |
21 | Clinicopathologic Features of Advanced Squamous NSCLC | Journal of Thoracic Oncology | 2016 | 101 |
22 | Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study | American Journal of Respiratory and Critical Care Medicine | 2019 | 96 |
23 | ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer | ESMO Open | 2020 | 96 |
24 | Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis | Thorax | 2019 | 88 |
25 | Challenges in lung cancer therapy during the COVID-19 pandemic | Lancet Respiratory Medicine,the | 2020 | 88 |
26 | Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ) | European Journal of Cancer | 2020 | 86 |
27 | Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study | Annals of Oncology | 2013 | 76 |
28 | Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study | Journal of Clinical Oncology | 2023 | 75 |
29 | Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles | ERJ Open Research | 2019 | 72 |
30 | Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey | European Journal of Cancer | 2018 | 69 |
31 | Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials | American Journal of Respiratory and Critical Care Medicine | 2018 | 60 |
32 | Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension | Thorax | 2018 | 59 |
33 | ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD | International Journal of COPD | 2017 | 53 |
34 | Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315) | Lung Cancer | 2021 | 53 |
35 | Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial | Lancet Respiratory Medicine,the | 2022 | 53 |
36 | Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations | Expert Review of Respiratory Medicine | 2020 | 51 |
37 | KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC | Annals of Oncology | 2019 | 50 |
38 | Small cell lung cancer: a slightly less orphan disease after immunotherapy | Annals of Oncology | 2021 | 49 |
39 | Changes in IgE sensitization and total IgE levels over 20 years of follow-up | Journal of Allergy and Clinical Immunology | 2016 | 48 |
40 | Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma | Pulmonary Pharmacology and Therapeutics | 2017 | 47 |
41 | Noninvasive Analysis of Microbiome Dynamics in the Fruit Fly Drosophila melanogaster | Applied and Environmental Microbiology | 2013 | 46 |
42 | The H2S-generating enzymes cystathionine β-synthase and cystathionine γ-lyase play a role in vascular development during normal lung alveolarization | American Journal of Physiology - Lung Cellular and Molecular Physiology | 2015 | 46 |
43 | Brain Activation during Perception and Anticipation of Dyspnea in Chronic Obstructive Pulmonary Disease | Frontiers in Physiology | 2017 | 46 |
44 | Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial | | 2022 | 45 |
45 | Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial | Journal of Thoracic Oncology | 2022 | 43 |
46 | KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. | Journal of Clinical Oncology | 2019 | 42 |
47 | Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. | Journal of Clinical Oncology | 2020 | 42 |
48 | Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy | Lung Cancer | 2016 | 41 |
49 | Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer | Journal of Thoracic Oncology | 2019 | 41 |
50 | Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD | Pulmonary Pharmacology and Therapeutics | 2013 | 40 |